17 episodes

Ori Spotlight covers the latest in cell and gene therapy.

Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments.

Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect

Ori Spotlight Ori Biotech

    • Science

Ori Spotlight covers the latest in cell and gene therapy.

Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments.

Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect

    Mike Paglia - Chief Operating Officer, ElevateBio

    Mike Paglia - Chief Operating Officer, ElevateBio

    For Episode 17 of the Ori Spotlight Podcast, Jason C. Foster is joined by Mike Paglia, COO of ElevateBio, a centralized R&D and manufacturing company developing its own innovative cell and gene therapies.

    Mike has 20 years of experience in biotechnology, working across the industry from therapeutic antibody manufacturing to drug development. Together, Jason and Mike discuss how ElevateBio supports the cell and gene therapy industry, the long-term benefits of digital manufacturing processes, and the importance of removing the cost barrier to CGT.

    Learn more about Mike Paglia: LinkedIn

    • 52 min
    Kevin Kyle and Carol Houts - Germfree

    Kevin Kyle and Carol Houts - Germfree

    For episode 16 of the Ori Spotlight Podcast, Jason C. Foster is joined by Germfree CEO, Kevin Kyle and VP of Regulatory and Business Development, Carol Houts.

    Germfree specializes in the manufacture of mobile and modular cleanrooms, laboratory equipment, cGMP facilities and biosafety labs to deliver solutions across the life science spectrum.

    Together they sat down to explore how Germfree supported the industry through COVID-19 - adapting with innovation within decentralized manufacturing of cell therapy, and taking an ecosystem approach to address supply chain challenges.

    Learn more about Kevin Kyle: https://www.linkedin.com/in/kevin-kyle-1b9b39/ | Carol Houts: https://www.linkedin.com/in/carol-houts-46a628a/

    • 49 min
    Jo Anne Valentino - Chief Operating Officer, Minaris Regenerative Medicine

    Jo Anne Valentino - Chief Operating Officer, Minaris Regenerative Medicine

    For episode 15 of Ori Spotlight, Jason C. Foster is joined by Jo Anne Valentino, Chief Operating Officer at Minaris Regenerative Medicine as she shares her insights into cell and gene therapy development.  

    Jo Anne has extensive experience in pharmaceutical manufacturing, having previously held senior positions at Merck and Novartis. Minaris Regenerative Medicine is a CDMO dedicated to the production of CGT products, offering high-quality clinical and commercial manufacturing services, developmental solutions and technologies.  

    Together, Jason and Jo Anne discuss how digital transformation can support scalability within CGT manufacturing, what can be learned from pharmaceutical supply chains, and the challenges faced within the CDMO industry.

    Learn more about Jo Anne: https://www.linkedin.com/in/jo-anne-valentino/

    • 44 min
    John Connolly - Chief Scientific Officer, Parker Institute for Cancer Immunotherapy

    John Connolly - Chief Scientific Officer, Parker Institute for Cancer Immunotherapy

    In episode 14 of the Ori Spotlight Podcast, Jason C. Foster is joined by John Connolly, Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy, who explained why and how the industry needs to increase the accessibility of CGT for patients.

    The Parker Institute is a research institute on a mission – to break down infrastructure barriers that have slowed progress in the development of immunotherapies. Their infrastructure builds collaboration between researchers, non-profits and industry organizations to bring treatments to patients faster.

    John sat down with Jason to discuss the value of academia and industry collaborations, the importance of flexibility and scalability in CGT manufacturing, and how as an industry we should measure the success of CGT.


    Learn more about John Connolly: https://www.linkedin.com/in/john-connolly-205b337/

    • 45 min
    Mike Nicholson & Matt Haines - Inceptor Bio

    Mike Nicholson & Matt Haines - Inceptor Bio

    In episode 13 of the Ori Spotlight Podcast Jason C. Foster sits down with Mike Nicholson (President and Chief Operating Officer) and Matt Haines (Vice President of Manufacturing Operations) at Inceptor Bio, as they share their insights into the cell and gene therapy space.

    Inceptor Bio is on a mission to cure difficult to treat cancers using next-generation cell therapy platforms. Their unique partnership model, with university oncology research programs, leverages their manufacturing resources and expert cell and gene therapy skills, to advance therapeutics into the clinic.

    Mike and Matt catch up with Jason to discuss the opportunities and challenges of CGT manufacturing, bringing CGT to patients at scale and what they envision for the future of CGT.

    Learn more about:

    Mike Nicholson - LinkedIn | Matt Haines - LinkedIn

    • 47 min
    Adam Wieschhaus and Shaan Gandhi - Directors, Northpond Ventures

    Adam Wieschhaus and Shaan Gandhi - Directors, Northpond Ventures

    In Episode 12 of the Ori Spotlight Podcast, Jason C. Foster sits down with Northpond Ventures, investor in both Ori’s Series A and Series B funding. We caught up with Directors Adam Wieschhaus and Shaan Gandhi, as they share their insights into the cell and gene therapy space. 

    Northpond Ventures is a $2.15 billion venture capitalist firm focused on life science, medicine, and technology; with 60 investments to date since its inception. Adam and Shaan lead their San Francisco and Boston offices respectively. 

    Adam and Shaan sit down with Jason to discuss why bringing scalable cell and gene therapies to market is vital, the impact these therapies have on patients, and what excites them most about the investments made within the CGT space.

    Learn more about:


    Adam Wieschhaus | https://www.linkedin.com/in/adamwieschhaus/
    Shaan Gandhi | https://www.linkedin.com/in/shaangandhi/

    • 50 min

Top Podcasts In Science

BBC Radio 4
The Bertarelli Foundation
BBC Radio 4
Hidden Brain
Sam Harris
Alie Ward

You Might Also Like